Navigation Links
Ardea Biosciences Announces Upcoming Corporate Meetings
Date:5/14/2008

very and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in a human micro-dose pharmacokinetic study and have selected it as a development candidate. We are also investigating RDEA806 for the treatment of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers for the treatment of inflammatory diseases. We have evaluated our second generation MEK inhibitor, RDEA436, for the treatment of cancer and inflammatory diseases in a human micro-dose pharmacokinetic study, and have selected it as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinica
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
2. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
3. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
4. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
5. Numira Biosciences Names New Board Member
6. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
7. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
8. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
9. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
10. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... Consumers overwhelmingly prefer to have their ... according to a new survey that also offers insight on why that is ... which reflects views on cosmetic medical treatments and ratings for 10 specific procedures ...
(Date:9/1/2015)... Houston, TX (PRWEB) , ... September 01, 2015 ... ... announce that it is now offering the MonaLisa Touch® , an innovative ... , The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among ... Math) disciplines since its inception more than 35 years ago. A pilot program begun ... their teachers - and, not just those intent on pursuing careers in these fields. ...
(Date:9/1/2015)... ... 01, 2015 , ... WorkCare, Inc., a national occupational health ... team as an Associate Medical Director. , WorkCare specializes in workforce health ... and abroad. , Dr. Nelson has a diverse background. He trained in ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... A new poll by Irishhealth.com has indicated the meager ... hospitals in the Irish Health Service. //Only one among ... ,The 40-bed Whitfield Clinic in Waterford and the 183-bed ... in healthcare. Of the registered users who were queried, ...
... new website launched to give online support to people ... 'Our Choices in Mental Health', the new national framework ... local level. // ,The Department of Health ... with these measures. The report, Our Choices in Mental ...
... study, the risk of developing pancreatic cancer increases by 90% with ... cancer risk was 70% higher in people who added sugar to ... compared with those who added no sugar. ,In spite ... it is for the first time that researchers have shown a ...
... of a controversial shake-up of hospital services in east Lancashire ... // ,East Lancashire Hospitals NHS Trust has ... A&E department that will now not be referred to the ... the decision that they have taken has granted the trust ...
... anti-polio drive Sunday even as new polio cases - three in ... ,During the drive, pulse polio drops would be administered to nearly ... to health officials here. , ,The latest case of ... 4 when Ajay, a 19-month-old baby in Jhabua district, was found ...
... Journal Of American Medical Association announced that having high blood ... In fact a theory by Dr. Mihai Gheorghiade of Northwestern ... blood to be viewed in new light. ,Dr. ... admission if a patient with heart failure continues to have ...
Cached Medicine News:Health News:New Website For People With Mental Problems 2Health News:Fury over Backing of Health Shake-up 2
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: